Published

Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Toxics
Date: 2023-02-03
Source: PubMed
DOI: 10.3390/toxics11020148
PubMed: 36851023

Authors

Henríquez-Hernández LA Rojas-Hernández J Quintana-Hernández DJ Borkel LF

Watch author

Derived topics and classifications

psilocybin Mechanism of Action Systematic Review Review Article Safety Toxicity Systematic Review

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

G33 Psychedelic drugs for the treatment of chronic pain: is ketamine included?Ask the expert - Psychedelic substances · 2024-08-31 Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility.Frontiers in neuroscience · 2026-01-01 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24 The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy TrainingClinicalTrials.gov · 2025-04-14 Retrospective Observational Study of Intensity Effects in Psychedelic-assisted TreatmentClinicalTrials.gov · 2025-10-02 Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)ClinicalTrials.gov · 2025-03-27 [Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland].Laeknabladid · 2023-11-01 LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II StudyClinicalTrials.gov · 2021-12-22